Challenges in the design and conduct of phase III brain tumor therapy trials

Neurology

Volumn 49, Issue 4, 1997, Pages 912-917

  Perry, J R ^a,j   Deangelis, L M ^a,i   Schold, S C ^a,h   Burger, P C ^g   Brem, H ^f   Brown, M T ^e   Curran, W J ^d   Scott, C B ^d   Prados, M D ^c   Kaplan, R ^b   Cairncross, J G ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOCHONDRIAL DNA;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; GLIOMA; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030693657     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.4.912     Document Type: Review

References (51)

1. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU anoVor radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978;49:333-343.
2. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:13231329.
3. Fine HA. The basis of current treatment recommendations for malignant glioma. J Neurooncol 1994;20:111-120.
4. Macdonald DR, Cascino TL, Schold SO, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
5. Cairncross JG, Macdonald DR, Pexman JHW, et al. Steroidinduced CT changes in patients with recurrent malignant glioma. Neurology 1988;38:724-726.
6. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroidinduced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886-1889.
7. Cairncross JG, Macdonald DR, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12: 2013-2021.
8. Cairncross JG, Eisenhauer EA. Response and control: lessons from oligodendroglioma [letter]. J Clin Oncol 1995;13:24752476.
9. Florell RC, Macdonald DR, Irish WD, et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992;76: 179-183.
10. Shapiro WR, Green S, Burger P, et al. A randomized trial of interstitial radiotherapy (IRT) boost for the treatment of newly diagnosed malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, malignant mixed glioma): BTCG study 8701 [abstract]. Neurology 1994;44(suppl 2):A263.
11. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-710.
12. Kirby S, Brothers M, Irish W, et al. Evaluating glioma therapies: modeling treatments and predicting outcomes. J Natl Cancer Inst 1995;87:1884-1888.
13. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-781.
14. Loeffler JS, Alexander E, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992;10:1379-1385.
15. Loefiler JS, Shricve DC, Wen PY, et al. Radiosurgery for intracranial malignancies. Semin Radiât Oncol 1995;5:225-234.
16. Curran WJ, Scott CB, Weinstein AS, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of the Radiation Therapy Oncology ' Group. J Clin Oncol 1993;ll:857-862.
17. Sarkaria JN, Mehta MP, Loeffler JS, et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int J Radiât Oncol Biol Phys 1995;32:931-941.
18. Irish WD, Macdonald DR, Cairncross JG. To randomize or not to randomize: using a database to answer the question. Can J Neurol Sci 1997 (in press).
19. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994;272:122-124.
20. Lachin JM, Foulkes MA. Evaluation of sample sizes and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, non compliance, and stratification. Biometrics 1986;42:507-516.
21. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centered approach to determining clinically important effect sizes for randomized treatment? J Clin Epidemiol 1994; 47:787-795.
22. Yusuf S, Wittes J, Probtsfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-98.
23. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q TWiST. The International Breast Cancer Study Group. Cancer Treat Rep 1993;19(suppl A):73-84.
24. Schwartz CE, Cole BF, Gelber RD. Measuring patientcentered outcomes in neurologic disease. Extending the QTWiST method. Arch Neurol 1995;52:754-762.
25. Murray KJ, Nelson DF, Scott C, et al. Quality-adjusted survival analysis of malignant glioma patients treated with twice-daily radiation and carmustine: a report of the Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiât Oncol Biol Phys 1995;31:453-459.
26. Gotay CC, Korn EL, McCabe MS. Quality of life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992;84:575-579.
27. Edland RW, Javid M, Ansfield FJ. Glioblastoma multiforme: an analysis of the results of postoperative radiotherapy alone versus radiotherapy and concomitant 5-fluorouracil: a prospective randomized study of 32 cases. Am J Roentgenol Rad Ther Nucl Med 1971;lll:337-342.
28. Schag CG, Heinrich RL, Ganz PA. Karnofsky Performance Status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-193.
29. Mackworth N, Fobair P, Prados MD. Quality of life self reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol 1992;14:243253.
30. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
31. Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995;75:1151-1161.
32. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 1993;ll:570-579.
33. MRC Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neurooncol 1990;9:47-55.
34. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 1996;14:1364-1370.
35. Kraus JA, Koopman J, Kaskel P, et al. Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95.
36. Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosom Cancer 1995;12: 277-282.
37. Kim L, Hochberg FH, Thorton AF, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996;85:602-607.
38. Scott CB, Nelson JS, Farran NC, et al. Central neuropathology review in clinical trials for patients with malignant glioma: a report of the RTOG 83-02. Cancer 1995;76:307-313.
39. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993;3:255-268.
40. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-2165.
41. Kirn TS, Halliday AL, Hedley-White ET, et al. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 1991;74:27-37.
42. Salcman M. Surgery for malignant gliomas. In: Morantz RA, Walsh JVV, eds. Brain tumors-a comprehensive text. New York: Marcel Dekker, 1994:417-427.
43. Curran WJ Jr, Scott CB, Horton J, et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? J Neurooncol 1992;12:219-227.
44. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487-493.
45. Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: outcome evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994;34:45-61.
46. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338-343.
47. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-1012.
48. Fine HA, Dear KBG, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant glioma in adults. Cancer 1993;71:2585-2597.
49. Borzak S, Ridker PM. Discordance between meta-analysis and large-scale randomized, clinical trials. Ann Intern Med 1995; 123:873-877.
50. Detsky AS, Naylor CD, O'Rourke K, et al. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992;45:255-265.
51. Levin VA, Silver P, Hannigan J, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiât Oncol Biol Phys 1990; 18:321-324.